Financings/Collaborations In Brief: Oravax
Executive Summary
Oravax: Public offering of 2 mil. shares at $7.25 per share will raise $14.5 mil. for the Cambridge, Mass. oral vaccines and non-injected antibody products company. Cowen & Co. and Donaldson, Lufkin & Jenrette are managing underwriters and have a 300,000 share over-allotment option...